Sign inJoin waitlistJoin the waitlist

Ticiana Leal

Physician · Emory Rehabilitation Hospital

Credentials: · · · · ·

History

Emory Rehabilitation Hospital
2026–Present

University of Wisconsin Hospitals and Clinics
2010–2012
Geriatric Medicine
University of Illinois College of Medicine at Chicago
2009–2010
University of Wisconsin School of Medicine and Public Health
2007–2009
University of Illinois College of Medicine at Chicago
2006–2007
Louis A Weiss Memorial Hospital
2003–2006
Faculdade de Medicina da Universidade Federal do Ceará
1997–2001

Research

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2017 · 1,060 citations
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
Journal of Clinical Oncology · 2021 · 978 citations
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021
Journal of the National Comprehensive Cancer Network · 2021 · 813 citations

Suresh Ramalingam
17 papers
Jennifer Carlisle
9 papers
Karen Reckamp
7 papers
GO
Gregory Otterson
6 papers
Jhanelle Gray
6 papers
Joel Neal
6 papers
Joshua Lang
6 papers
LH
Leora Horn
6 papers
Sandip Patel
6 papers
Thomas Dilling
6 papers
Wallace Akerley
6 papers
AT
Anne Traynor
5 papers

Grants

ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
National Cancer Institute · UG1
Contact PI · $2.7M · Emory University
2019–2027

Clinical trials

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2020–2027
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2018–2025
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Site PI · Recruiting · Phase 3
Nuvalent Inc.
2025–2029
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2025–2029